NAD+ Biology and Age-Related Decline
NAD+ (nicotinamide adenine dinucleotide) is not a single-function coenzyme — it is a biochemical hub molecule whose redox cycling underpins the entirety of cellular energy metabolism, while its consumption as a substrate drives DNA repair, gene silencing, and circadian rhythm maintenance. This duality is what makes its age-related decline so consequential: a falling NAD+ pool does not merely slow one process, it simultaneously degrades the function of every system that depends on it.
The 50% Decline: Magnitude and Tissue Distribution
Landmark tissue surveys — including the Verdin laboratory analysis of human skeletal muscle, liver, brain, and skin biopsies — have documented approximately a 50% reduction in NAD+ concentration between the third and sixth decade of life. This is not a marginal perturbation; a halving of the available NAD+ pool has consequences that ripple across every pathway described above simultaneously. Skeletal muscle is particularly affected given its high mitochondrial density and corresponding oxidative NAD+ demand, but the decline is systemic.
The mechanistic architecture of this decline involves three competing depletion pathways that amplify one another in a cascade. CD38 NADase activity increases with age — driven in large part by chronic low-grade inflammation (inflammaging) that activates NF-κB, the transcription factor that upregulates CD38 expression. As cellular NAD+ falls, the DNA damage response becomes less effective, leading to accumulation of unrepaired lesions. PARP1 is then chronically activated in response to this escalating DNA damage burden, consuming further NAD+. Meanwhile, reduced NAMPT expression constrains the salvage pathway's capacity to regenerate what has been consumed. The result is a self-reinforcing depletion cycle in which the three principal consumers — CD38, PARP1, and paradoxically the sirtuin enzymes themselves (whose function requires NAD+) — compete for an ever-shrinking substrate pool.
Elevated CD38 → NAD+ falls → PARP1 inefficiency → DNA damage accumulates → PARP1 further activated → NAD+ falls further → sirtuin function impaired → epigenetic maintenance fails → gene expression dysregulation → further cellular stress → CD38 re-activated via NF-κB. Understanding this cascade is central to evaluating precursor supplementation strategies, which aim to interrupt the cycle at the NAMPT-NMN step.
Sirtuins: The NAD+-Dependent Longevity Enzymes
The sirtuin family comprises seven NAD+-dependent deacylases (SIRT1–7) with distinct subcellular localisations and substrate profiles. Unlike kinases or phosphatases that modulate signalling through phosphorylation states, sirtuins operate at the level of chromatin architecture — removing acetyl groups from histone and non-histone proteins to regulate gene expression, DNA repair fidelity, and metabolic enzyme activity. Their dependence on NAD+ as a stoichiometric co-substrate — not a cofactor that is recycled — means sirtuin activity is exquisitely sensitive to changes in the intracellular NAD+/NADH ratio.
The Km Argument: Why NAD+ Concentration Matters
The Michaelis constant (Km) for NAD+ in SIRT1 activity assays is approximately 94–880 µM depending on the substrate and assay conditions, while SIRT3 has a Km of around 880 µM. Measured intracellular NAD+ concentrations in aged human tissue fall to the 300–500 µM range in muscle — approaching or falling below the Km for SIRT3 and into the steeply declining portion of the SIRT1 activity curve. In practical terms: at the NAD+ concentrations present in aged tissue, sirtuins operate at a fraction of their Vmax. This kinetic constraint, rather than any change in sirtuin protein expression per se, is increasingly understood as the primary mechanism by which sirtuin-mediated epigenetic maintenance fails during ageing.
PARP–Sirtuin Competition: The Aged-Cell Dilemma
Perhaps the most clinically significant consequence of age-related NAD+ depletion is the competitive dynamic between PARP1 and the sirtuin family for the limited NAD+ pool. PARP1 has a substantially higher affinity for NAD+ than sirtuins (Km ~20–97 µM), meaning that when DNA damage is present, PARP1 out-competes sirtuins for the available substrate. In young, high-NAD+ cells, both pathways can be adequately supplied. In aged, low-NAD+ cells with an escalating DNA damage burden, PARP1 activation effectively shunts the entire remaining NAD+ supply into the DNA repair response — at the direct expense of sirtuin-mediated epigenetic maintenance, PGC-1α-driven mitochondrial biogenesis, and FOXO-regulated stress response gene expression.
The Camacho-Pereira et al. (2016) study in Cell Metabolism demonstrated that CD38 knockout mice — which maintain elevated NAD+ levels with ageing — show preserved SIRT3 activity, reduced mitochondrial protein acetylation, and significantly attenuated age-associated metabolic decline. This genetic evidence directly implicates the CD38→NAD+↓→SIRT3↓→mitochondrial dysfunction axis as a tractable target and validates the conceptual basis for NAD+ precursor strategies in ageing research models.
NMN and NR: Precursor Research and Bioavailability Comparison
Because NAD+ itself does not readily cross cell membranes via passive diffusion, research into NAD+ restoration has focused on biosynthetic precursors that enter the intracellular salvage pathway and are converted to NAD+ by endogenous enzymes. The two most extensively studied oral precursors are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside), both of which feed into the Preiss-Handler salvage pathway via distinct entry points. Direct intravenous NAD+ infusion has also been employed in clinical research settings where higher peak tissue concentrations are required.
Salvage Pathway Entry Points
NMN enters the salvage pathway directly as a substrate for NMN adenylyltransferases (NMNAT1–3), which convert it to NAD+. The rate-limiting step in NMN bioavailability was long debated — a 2019 report proposed that a dedicated NMN transporter (Slc12a8) facilitates direct cellular import of intact NMN in the mouse intestine, bypassing the need for extracellular dephosphorylation to NR. NR enters the pathway via nicotinamide riboside kinases (NRK1 and NRK2), which phosphorylate it to NMN, which is then adenylylated to NAD+. Both precursors ultimately converge on NAMPT as the primary regenerative enzyme for the nicotinamide→NMN step of the canonical salvage cycle.
| Metric | NMN (oral) | NR (oral) | NAD+ IV Infusion |
|---|---|---|---|
| Salvage entry point | NMNAT1–3 (direct NMN→NAD+) | NRK1/2 (NR→NMN→NAD+) | Direct (extracellular → tissue) |
| Oral bioavailability | Moderate; absorbed intact in small intestine (Slc12a8 transporter); partial conversion to NR/NAM before absorption | Well-characterised; absorbed as NR and NAM; NR bioavailability documented in Trammell 2016 human trial | Not applicable — bypasses GI tract entirely |
| Peak NAD+ elevation | Significant skeletal muscle NAD+ rise demonstrated in Yoshino M 2021 (250 mg/day, 10 weeks) | Dose-dependent blood NAD+ elevation in Trammell 2016; tissue distribution less characterised than NMN | Highest achievable peak tissue NAD+; used in clinical settings for rapid repletion |
| Human trial evidence | Yoshino M et al. Science 2021 (PMID 34108264): improved insulin sensitivity in postmenopausal prediabetic women; Yoshino J et al. Cell Metab 2021 (PMID 34748701): age-specific metabolic response | Trammell SA et al. Nat Commun 2016 (PMID 27721237): first demonstration of oral NR bioavailability and blood NAD+ metabolome elevation in healthy humans | Clinical series; no large RCT; pharmacokinetic data from open-label studies |
| Key animal data | Mills KF et al. Cell Metab 2016 (PMID 28068222): 12-month NMN in aged mice reversed multiple age-associated physiological markers including muscle, eye, bone density, energy metabolism, and immune function | Cantó C et al. Cell Metab 2012: NR supplementation elevated NAD+, activated SIRT1/SIRT3, and prevented high-fat-diet-induced metabolic dysfunction in mice | Rapid tissue NAD+ saturation; translational utility limited by route practicality |
| Stability | Stable as lyophilised powder; NAD+ in solution degrades rapidly — 7-day post-reconstitution window at 2–8°C | Stable as solid; hygroscopic; store desiccated | Prepared fresh; minimal shelf-life in solution |
The Yoshino M 2021 Human Trial
The most cited human NMN trial — Yoshino M et al., published in Science in 2021 — enrolled postmenopausal women with prediabetes and administered 250 mg/day oral NMN for 10 weeks in a randomised, placebo-controlled crossover design. Skeletal muscle biopsy NAD+ metabolomics confirmed tissue-level NAD+ elevation in the NMN arm. The primary metabolic outcome — insulin-stimulated glucose disposal in skeletal muscle — was significantly improved, with the effect attributed to NMN-driven upregulation of insulin signalling gene expression (specifically genes downstream of the insulin receptor substrate pathway in muscle). Critically, this trial provided the first human tissue-level confirmation that oral NMN reaches skeletal muscle and elevates local NAD+ metabolites — addressing a longstanding question about whether precursor supplementation translates from mouse to human tissue pharmacokinetics.
The Mills 2016 Aged Mouse Study
Mills KF et al. (2016) in Cell Metabolism represent the landmark long-duration preclinical study in the field. Aged mice (18–24 months) administered NMN in drinking water for 12 months showed attenuation of multiple age-associated physiological decline markers: improved energy metabolism (oxygen consumption rate, physical activity), skeletal muscle mass and function, eye function, bone density, plasma lipid profile, and immune function. The study's strength is its duration and breadth of outcome measures — demonstrating that sustained NAD+ precursor availability modulates the trajectory of ageing phenotypes across multiple organ systems simultaneously, consistent with the systemic role of NAD+ as a universal redox and signalling hub.
NAD+ in aqueous solution undergoes rapid non-enzymatic hydrolysis at physiological pH, particularly at temperatures above 4°C. Research protocols using reconstituted NAD+ should adhere strictly to a 7-day use window with continuous storage at 2–8°C. Repeated freeze-thaw cycling accelerates degradation. Lyophilised NMN and NR precursor powders are substantially more stable and should be the preferred format for any protocol requiring consistent potency across extended experimental timelines. For NAD+ IV preparations used in clinical research settings, fresh preparation on the day of use is standard practice.
